Taming the SARS-CoV-2-mediated proinflammatory response with BromAc®
Description
CONCLUSION: These results give new insights into the mechanisms for the robust anti-inflammatory effect of BromAc® in the steady state and SARS-CoV-2-specific immune leukocyte responses, indicating its potential as a therapeutic strategy for COVID-19
